Prospective study assessing hypoxia-related proteins as markers for the outcome of treatment with sunitinib in advanced clear-cell renal cell carcinoma

Annals of Oncology

Volumn 24, Issue 9, 2013, Pages 2409-2414

  Garcia Donas, J ^a,b,c   Leandro Garcia L J ^c   Gonzalez del Alba A ^b,d   Morente, M ^c   Alemany, I ^e   Esteban, E ^b,f   Arranz, J A ^b,g   Climent, M A ^b,h   Gallardo, E ^b,i   Castellano, D E ^b,j   Bellmunt, J ^b,k,l   Mellado, B ^b,m   Puente, J ^b,n   Moreno, F ^b,n   Font, A ^a,o   Hernando, S ^e   Robledo, M ^c,p   Rodriguez Antona C ^c,p  

^a Centro Integral Oncologico Clara Campal   (Spain)

^b Spanish Oncology GenitoUrinary Group ^*  (Spain)

^c Centro Nacional de Investigaciones Oncológicas   (Spain)

^d HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^e HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^f HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^g HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^h INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

ⁱ Hospital Universitari Parc Taulí   (Spain)

^j HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^k HOSPITAL DEL MAR   (Spain)

^l HARVARD MEDICAL SCHOOL   (United States)

^m HOSPITAL CLÍNIC   (Spain)

ⁿ HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^o HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^p CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

more..

Author keywords

EGLN3; Hypoxia; Immunohistochemistry; Predictive marker; Renal carcinoma; Sunitinib

Indexed keywords

ANGIOGENESIS INHIBITOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN CAIX; SUNITINIB; TUMOR MARKER; TUMOR PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; VON HIPPEL LINDAU PROTEIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER PROGNOSIS; CELL HYPOXIA; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; EGLN3 GENE; ENZYME INACTIVATION; EXPLORATORY RESEARCH; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; ONCOGENE; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN POLYMORPHISM; RNA ANALYSIS; SURVIVAL TIME; TREATMENT OUTCOME;

EGLN3; HYPOXIA; IMMUNOHISTOCHEMISTRY; PREDICTIVE MARKER; RENAL CARCINOMA; SUNITINIB;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CARCINOMA, RENAL CELL; CELL HYPOXIA; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION; HUMANS; HYPOXIA-INDUCIBLE FACTOR-PROLINE DIOXYGENASES; IMMUNOHISTOCHEMISTRY; INDOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROSPECTIVE STUDIES; PYRROLES; RNA, MESSENGER; SURVIVAL; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3;

EID: 84883430506     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt219     Document Type: Article

References (23)

1. Gupta K, Miller JD, Li JZ et al. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev 2008; 34: 193-205.
2. Escudier B, Szczylik C, Porta C, et al. Treatment selection in metastatic renal cell carcinoma: expert consensus. Nat Rev Clin Oncol 2012; 9: 327-337.
3. Rodriguez-Antona C, Garcia-Donas J. Constitutional genetic variants as predictors of antiangiogenic therapy outcome in renal cell carcinoma. Pharmacogenomics 2012; 13: 1621-1633.
4. Perez-Gracia JL, Prior C, Guillen-Grima F, et al. Identification of TNF-alpha and MMP-9 as potential baseline predictive serum markers of sunitinib activity in patients with renal cell carcinoma using a human cytokine array. Br J Cancer 2009; 101: 1876-1883.
5. Gruenwald V, Beutel G, Schuch-Jantsch S, et al. Circulating endothelial cells are an early predictor in renal cell carcinoma for tumor response to sunitinib. BMC Cancer 2010; 10: 695.
6. Rini BI, Jaeger E, Weinberg V, et al. Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status. BJU Int 2006; 98: 756-762.
7. Choueiri TK, Vaziri SA, Jaeger E, et al. von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. J Urol 2008; 180: 860-865; discussion 865-866.
8. Pena C, Lathia C, Shan M, et al. Biomarkers predicting outcome in patients with advanced renal cell carcinoma: results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial. Clin Cancer Res 2010; 16: 4853-4863.
9. Motzer RJ, Hutson TE, Hudes GR, et al. Novel circulating proteins, single nucleotide polymorphisms, and molecular tumor markers as potential biomarkers of sunitinib efficacy in treatment-naive patients with advanced renal cell carcinoma. Abstract, ESMO 2012 Congress 2012.
10. Gossage L, Eisen T. Alterations in VHL as potential biomarkers in renal-cell carcinoma. Nat Rev Clin Oncol 2010; 7: 277-288.
11. Choueiri TK, Regan MM, Rosenberg JE, et al. Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clearcell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy. BJU Int 2010; 106: 772-778.
12. Patel PH, Chadalavada RS, Ishill NM, et al. Hypoxia-inducible factor (HIF) 1alpha and 2alpha levels in cell lines and human tumor predicts response to sunitinib in renal cell carcinoma (RCC). J Clin Oncol 2008; 26: Abstract 5008.
13. Dalgliesh GL, Furge K, Greenman C, et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 2010; 463: 360-363.
14. Garcia-Donas J, Esteban E, Leandro-Garcia LJ, et al. Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study. Lancet Oncol 2011; 12: 1143-1150.
15. Smith NR, Baker D, James NH, et al. Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancers. Clin Cancer Res 2010; 16: 3548-3561.
16. Rini BI, Michaelson MD, Rosenberg JE, et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol 2008; 26: 3743-3748.
17. Deprimo SE, Bello CL, Smeraglia J, et al. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J Transl Med 2007; 5: 32.
18. Kontovinis LF, Papazisis KT, Touplikioti P, et al. Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers. BMC Cancer 2009; 9: 82.
19. Kim JJ, Vaziri SA, Rini BI, et al. Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib. Cancer 2012; 118: 1946-1954.
20. Paule B, Bastien L, Deslandes E, et al. Soluble isoforms of vascular endothelial growth factor are predictors of response to sunitinib in metastatic renal cell carcinomas. PLoS One 2010; 5: e10715.
21. Phuoc NB, Ehara H, Gotoh T, et al. Prognostic value of the co-expression of carbonic anhydrase IX and vascular endothelial growth factor in patients with clear cell renal cell carcinoma. Oncol Rep 2008; 20: 525-530.
22. Jacobsen J, Grankvist K, Rasmuson T, et al. Expression of vascular endothelial growth factor protein in human renal cell carcinoma. BJU Int 2004; 93: 297-302.
23. Gad S, Sultan-Amar V, Meric J-B, et al. Somatic von Hippel-Lindau (VHL) gene analysis and clinical outcome under antiangiogenic treatment in metastatic renal cell carcinoma: preliminary results. Target Oncol 2007; 2: 3-6.